Copyright
©2013 Baishideng Publishing Group Co.
World J Hepatol. Mar 27, 2013; 5(3): 114-119
Published online Mar 27, 2013. doi: 10.4254/wjh.v5.i3.114
Published online Mar 27, 2013. doi: 10.4254/wjh.v5.i3.114
Stents used (n) | 48 |
Stent deployment | |
Y-configuration | 18/35 (51.4%) |
T-configuration | 17/35 (48.6%) |
Technical success | 35/35 (100%) |
Clinical success | 27/35 (77.1%) |
Decreased bilirubin levels | 27/33 (81.8%) |
Serum bilirubin decrease | 60.5% (23%-92%) |
Survival interval (d), mean (range) | 168 (0-1763) |
6-mo survival rate | 47.10% |
Primary patency (d), mean (range) | 105 ( 0-719) |
Secondary patency (d), mean (range) | 181 (100-1763) |
Peri-procedural death | 2/35 (5.7%) |
Major complications | 2/35 (5.7%) |
Minor complications | 6/35 (17.1%) |
Hospitalization time (d), mean ± SD | 10.2 ± 3.9 |
- Citation: Karnabatidis D, Spiliopoulos S, Katsakiori P, Romanos O, Katsanos K, Siablis D. Percutaneous trans-hepatic bilateral biliary stenting in Bismuth IV malignant obstruction. World J Hepatol 2013; 5(3): 114-119
- URL: https://www.wjgnet.com/1948-5182/full/v5/i3/114.htm
- DOI: https://dx.doi.org/10.4254/wjh.v5.i3.114